Earnings call transcript: Burcon Q2 2026 revenue jumps as stock rises 3.6%
Burcon NutraScience reported that its fiscal second-quarter revenue surged nearly threefold compared to the same period last year, driven by increased sales of protein products and a growing customer base. The company's stock price appreciated by 3.57% to reach $0.87 following the earnings call. Management clarified that production issues, which affected operations during the quarter, were isolated infrastructure problems that have since been resolved.
Analysts were expecting a loss of $0.04 per share on revenue of $2.9 million. However, the company did not disclose actual EPS or revenue figures in the provided data. Nonetheless, analysts anticipate continued sales growth for the current year. The company currently has over 40 active customers and 209 projects in its pipeline, with 26 projects having progressed beyond the pallet-order stage.
Despite the significant year-over-year revenue growth of 557%, sequential revenue declined by 18% due to timing and production constraints. Operating losses, however, improved by 2% sequentially, indicating better cost control measures. The company has secured a CAD 4.2 million unsecured loan, with a larger financing arrangement currently in progress.
Burcon's stock is currently valued at $7.45 million, reflecting its small-cap status. The company is operating five days a week, 24 hours a day, and plans to expand to seven-day operations. Management sees a potential revenue run rate of over $10 million and positive cash flow by the end of 2027. The stock is currently trading below its 52-week range of $0.56 to $1.75 and is down 46.6% year-to-date and 55% over the past year.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.